EDISON EQUITY RESEARCH: BELLUS HEALTH - AA AMYLOIDOSIS PIVOTAL STUDY FULLY ENROLLED Bellus’s lead candidate, Kiacta, recently reached full...
Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs and BELLUS Health...
- Auven Therapeutics and BELLUS Health Amend the KIACTA™ Asset Purchase and Licensing Agreement - Auven Therapeutics, the global private...
Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs and Bellus Health...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-CSR CERTIFIED SHAREHOLDER...
In preparation for its reorganization into Westcore Blue Chip Fund, the Directors of Blue Chip Value Fund, Inc. (NYSE: BLU...
000 B000000 12/31/2010 000 C000000 0000810439 000 D000000 N 000 E000000 NF 000 F000000 Y 000 G000000 N 000 H000000 N 000 I000000 6.1 000 J000000...
Blue Chip Value Fund, Inc. (NYSE:BLU) announced today that its stockholders have approved the reorganization of the Fund into...
Blue Chip Value Fund (NYSE: BLU), today, announced that the $0.0178 annual dividend, payable January 14, 2011, for 2010 was from...
The Directors of Blue Chip Value Fund, Inc. (NYSE: BLU) have declared a distribution of $0.0178 per share. This distribution is...
SCHEDULE 13D DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT 12/02/2010 1. NAME OF REPORTING PERSON Bulldog Investors, Brooklyn Capital...
Chubb Group of Insurance Companies DECLARATIONS ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO...
NEWS RELEASE FOR IMMEDIATE RELEASE DATE:...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.